FORCE: Focus on Reducing Dose-Limiting Toxicities in Colon Cancer with Resistance Exercise
To examine differences in dose reductions, dose delays and early stoppage for chemotherapy and the total combined number of moderate and severe chemotherapy-associated toxicities between intervention group and waitlist controls.
To examine specific inflammatory markers (e.g. CRP, IL-6, TNF-a receptor II [TNF-RII]) in relation to baseline MM and fat mass (FM) and examine differences in changes in inflammatory markers between intervention group and waitlist controls. Inflammatory markers and body composition will be measured pre and post intervention.
To examine the impact of RT induced body composition changes on the pharmacokinetics (PK) of 5-FU and oxaliplatin between baseline and 4 months of RT.